CLINICAL AND THERAPEUTIC STUDIES IN HUMAN FILARIASIS

两种新药的试验，invermectin（IIa期）和CGP-20376（I期）， 正在与印度马德拉斯的调查人员合作， 治疗班氏丝虫病 热带肺结核患者支气管肺泡灌洗研究 嗜酸性粒细胞增多症显示持续性肺泡炎，尽管标准治疗 乙胺嗪（DEC），一项比较长期DEC或DEC加 类固醇和标准治疗已经开始 对在中西部工作的和平队志愿人员进行临床评价 非洲表示，当这些外籍人员进入Loa Loa流行地区时， 它们会对寄生虫产生免疫过敏， 出现严重的临床症状。 制定保护这些人的手段 预防性每周DEC的双盲试验 现在是第二年。

Trials of two new drugs, invermectin (Phase IIa) and CGP-20376 (Phase I), are being initiated in collaboration with investigators from Madras India for patients with bancroftian filariasis. Since bronchoalveolar lavage studies on patients with tropical pulmonary eosinophilia show persistent alveolitis despite standard therapy with diethylcarbamazine (DEC), a trial comparing long-term DEC or DEC plus steroids with standard therapy has commenced. Clinical evaluation of Peace Corps Volunteers working in Central/West Africa indicates that when such expatriates enter Loa loa endemic areas, they become immunologically hypersensitive to the parasite and often develop severe clinical symptoms. To develop means for protecting such individuals from infection, a double-blind trial of prophylactic weekly DEC is now in its second year.